Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00737893 · ClinicalTrials.gov registry record · Phase 2
Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
NCT00737893: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT00737893 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 56 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00737893, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
Study Summary
This research study aims to explore the effectiveness of human erythropoietin versus placebo in promoting the recovery of erectile function in patients undergoing bilateral nerve-sparing radical retropubic prostatectomy for clinically localized prostate cancer. Pre-clinical studies have shown erythropoietin potently promoted recovery of erectile function in rats and humans have similar receptors on penile tissues and the periprostatic neurovascular bundles. A clinical non-randomized study conducted in men undergoing radical prostatectomy demonstrated a benefit to recovery of erectile function. Therefore, the hypothesis is that erythropoietin offers nerve protection in men undergoing nerve-sparing radical prostatectomy and results in a reduced degree of erectile dysfunction and also an improved rate of erection recovery following surgery.
Interventions
- DRUG Placebo
- DRUG Erythropoietin (EPO)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2017-07-01 |
| Est. Completion | 2019-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00737893
The ClinicalTrials.gov registry entry for NCT00737893 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00737893 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00737893 about?
NCT00737893 is a clinical study titled "Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy". This research study aims to explore the effectiveness of human erythropoietin versus placebo in promoting the recovery of erectile function in patients undergoing bilateral nerve-sparing radical retropubic prostatectomy for clinically localized prostate cancer. Pre-clinical studies have shown eryth...
What is the current status of trial NCT00737893?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2017-07-01. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT00737893?
The interventions under investigation include: Placebo (DRUG), Erythropoietin (EPO) (DRUG).
Who is sponsoring clinical trial NCT00737893?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.